Two of the successful gene-directed enzyme prodrug therapies include herpes simplex virus-thymidine kinase (HSV1-TK) enzymeganciclovir prodrug and the Escherichia coli nitroreductase (NTR) enzyme-CB1954 prodrug strategies; these enzyme-prodrug combinations produce activated cytotoxic metabolites of the prodrugs capable of tumor cell death by inhibiting DNA synthesis and killing quiescent cells, respectively. Both these strategies also affect significant bystander cell killing of neighboring tumor cells that do not express these enzymes. We have developed a dual-combination gene strategy, where we identified HSV1-TK and NTR fused in a particular orientation can effectively kill tumor cells when the tumor cells are treated with a fusion HSV1-TK-NTR gene-along with a prodrug combination of GCV and CB1954. In order to determine whether the dual-system demonstrate superior therapeutic efficacy than either HSV1-TK or NTR systems alone, we conducted both in vitro and in vivo tumor xenograft studies using triple negative SUM159 breast cancer cells, by evaluating the efficacy of cell death by apoptosis and necrosis upon treatment with the dual HSV1-TK genes-GCV-CB1954 prodrugs system, and compared the efficiency to HSV1-TK-GCV and NTR-CB1954. Our cell-based studies, tumor regression studies in xenograft mice, histological analyses of treated tumors and bystander studies indicate that the dual HSV1-TK-NTR-prodrug system is two times more efficient even with half the doses of both prodrugs than the respective single gene-prodrug system, as evidenced by enhanced apoptosis and necrosis of tumor cells in vitro in culture and xenograft of tumor tissues in animals.
INTRODUCTION
Systemically administered conventional chemotherapeutic agents impart high levels of toxicity to both cancer and normal cells, resulting in significant side-effects, and lower treatment dosages. Gene-directed enzyme prodrug therapy (GDEPT) is an emerging strategy that involves tumor-targeted delivery of exogenous gene(s) that express enzyme(s) capable of converting non-toxic prodrug(s) into activated cytotoxic agent(s) that act locally within the tumor, causing cancer-specific cell death and lower toxicity to surrounding normal tissues. [1] [2] [3] The E. coli nitroreductase (NTR) gene, when selectively introduced into mammalian tumors, produces the tumor-localized NTR enzyme. As NTR is not naturally expressed in mammalian cells, a significant advantage of this system is tumor-restricted delivery of therapeutic prodrug, easy detection of the therapeutic outcome by using the imaging agent CytoCy5S 4 and the absence of nonspecific background effect from tissues. Following systemic administration of the nontoxic prodrug CB1954 (5-(aziridin-1-yl)-2,4-Dinitrobenzamide), the NTR enzyme converts the prodrug to its active cytotoxic form, (5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide), which creates DNA inter-strand crosslinks that are poorly repaired by cells, 5 thereby specifically killing cells expressing the enzyme (suicide gene therapy). 6 Other successful GDEPT strategies 7 include the combination of herpes simplex virus 1-thymidine kinase and prodrug ganciclovir (HSV1-TK-GCV), which is currently in clinical trials, 8, 9 and cytosine deaminase with 5-fluorocytosine (CD-5FC).
10, 11 The active metabolites of GCV and 5FC inhibit DNA synthesis, thereby killing mainly proliferating cells in S phase, 12 whereas activated CB1954 is toxic to both replicating and non-replicating cells. 6, 13 As only a minority of tumor cells replicate DNA at any particular time, it is advantageous to utilize a treatment strategy that kills tumor cells regardless of their replication status. NTR-CB1954 is expected to demonstrate superior GDEPT therapeutic efficacy, as it kills dividing, nondividing, and slowly dividing cancer cells (resistant to radio-and chemotherapy or involved in tumor recurrence), in combination with potent bystander effects.
14 As HSV1-TK/GCV and NTR/CB1954 is a well-validated system with proven clinical success, 15 and NTR-CB1954 system is currently in Phase I clinical trials, [16] [17] [18] [19] [20] we focused, in this study, on GDEPT strategies that have already been used successfully in human applications. We hypothesize that fusion of HSV1-TK and NTR will enable the development of a potentially superior dual gene (HSV1-TK-NTR)-dual prodrug (GCV-CB1954) system with superior tumor-cell killing and bystander effects compared with either strategies alone. When expressed in mammalian cells, NTR enzyme is localized in the cytoplasm, where it reacts with CB1954 and converts it into its toxic metabolite that can diffuse into the nucleus and effect the therapeutic outcome. In contrast, when NTR is expressed as a fusion protein with the nuclear enzyme TK, TK-NTR tends to home into the nucleus and convert the substrates CB1954 and GCV to their respective toxic metabolites, thereby permitting their rapid access to both DNA synthesis and DNA inter-strand crosslinking processes. The use of a combination HSV1-TK and CD with their respective prodrugs was previously shown with enhanced therapeutic efficiency in different human cancers in animals. [21] [22] [23] [24] Although HSV1-TK-GCV remains the most successful GDEPT strategy to date, high toxicity due to phosphorylation and activation of GCV by mammalian TK in normal cells remains a problem at high dosages. 25 The use of a dual HSV1-TK-NTR system would possibly lead to the use of reduced dosages of GCV during treatment by keeping increased therapeutic efficiency, partially contributed by NTR-CB1954 system, with the reduction in GCV associated toxicity to normal cells. In this study, we generate a dual HSV1-TK-NTR gene that expresses both HSV1-TK and NTR as a fusion protein, and investigate its therapeutic efficiency in vitro and in tumor xenografts of human breast cancer cells in mice following the treatment with prodrugs GCV and CB1954, and compare its effect with single HSV1-TK-GCV or NTR-CB1954 strategies. We study the effect of systemic administration of GCV and CB1954 on breast cancer cells expressing HSV1-TK and NTR, and perform non-invasive imaging of NTR-and TK-expressing tumor xenografts by optical fluorescence using CytoCy5S. We obtain rapid real-time data on the levels of NTR and HSV1-TK by optical imaging, analyze the synergistic effect of the dual-fusion HSV1-TK-NTR system in effecting enhanced tumor cell death, and study the improvement of overall therapeutic efficacy of this dualgene-prodrug strategy in GDEPT. Figure S1b) . We selected cells expressing these constructs (TK-and TK-NTR) for further evaluations in cell-based and tumor xenograft studies in living animals.
RESULTS

Characterization
Characterization of NTR expression and reduction of CytoCy5S substrate by NTR and TK-NTR cells CytoCy5S, an imaging substrate of NTR, was first utilized to characterize NTR functional efficiency in stable cells expressing the enzyme. CytoCy5S is a membrane-permeable quenched substrate that is reduced to a red-shifted fluorescence form by NTR enzyme. The fluorescent product is retained for prolonged period of time within the cells, making it a viable, consistent and non-toxic imaging agent. 4 Fluorescence-activated cell sorting (FACS) analysis was performed for quantitative evaluation of fluorescent signals from CytoCy5S reduction in stably transfected 293T, and SUM159-triple negative breast cancer cells, expressing NTR and TK-NTR. Results show more than a log-order elevation of fluorescent signals in NTR and TK-NTR containing cells than the control cells (Supplementary Figure S2 ; SUM159 cells), following 60 min exposure to the substrate (100 ng/ml). In order to determine the functional efficiencies of NTR enzymes in various stable lines used in these studies, and also to isolate cells expressing equal levels of functional NTR, stable SUM159 cells containing NTR and TK-NTR were incubated for 60 min with CytoCy5S (100 ng ml À 1 ) and the cells were FACS-sorted based on the levels of CytoCy5S reduction. Figure 1a shows a log-order increase in fluorescent signals compared with untreated controls, and equivalent efficiencies of CytoCy5S reduction by NTR enzymes expressed in both SUM159-NTR and SUM159-TK-NTR cells. Figure 1b illustrates that in both NTR-and TK-NTR-expressing stable 293T cells, CytoCy5S is reduced to its red-shifted form as measured by fluorescence signal intensities using a fluorescent microscope, demonstrating equivalent efficacy of NTR enzyme function in both stable clones. The main objective of this study is to apply the developed gene therapy in clinically relevant cancer type. As triple-negative breast cancer sub type is an aggressive phenotype and has no successful targeted therapy, we used SUM159 triple-negative breast cancer cells for the study. To sensitively evaluate bystander effect without any background cell death during staining procedures, it is important to collect cells without trypsinization. SUM159 cells are strongly adherent, and need significant trypsinization time to detach from culture plates, hence we used a weakly adherent HEK293 cells for some of our studies. Collectively, these data indicate that NTR enzyme expressed by NTR gene and TK-NTR fusion gene in stably transfected 293T cells and SUM159 breast To analyze whether 293T-TK-NTR demonstrates higher efficacy of cell death compared with 293T-NTR and 293T-TK, cells were treated with 1 mg ml À 1 GCV and 1 mM CB1954, 5 mM CB1954 or 10 mM CB1954, and analyzed for cell viability on days 1 through 5. Graphical representation ( Figure 3) shows that the maximal level of cell death is reached by TK-NTR treated with 1 mg ml À 1 GCV and 1 mM CB1954, whereas NTR requires 10 mM CB1954 to reach the same level of efficacy. These cell culture data indicate that TK-NTR would require lower dosages of prodrug for efficient cell killing. The above results also show that the NTR and TK-NTR fusion products are effectively able to sensitize cells to activated prodrugs and affect targeted cell death. Overall, the TK-NTR strategy demonstrates maximum Dual-therapeutic reporter genes fusion TV Sekar et al cell death or apoptosis when compared with NTR alone, and the efficacy improves with higher dosages of CB1954.
Comparison of TK-and TK-NTR bystander efficiency Bystander effects or killing of normal cells by therapeutic genecontaining cells treated with prodrug were studied in vitro. 293T normal cells were plated in different ratio (Table 1) Comparison of antitumor activities of NTR and TK-NTR in xenografts of breast cancer cells in mice While we performed our initial in vitro experiments with 293T cells, we opted to study antitumor efficacy of prodrug treatment using cancer cells to obtain valuable information regarding the contribution and efficacy of NTR and TK-NTR in treatment of cancer. The triple negative breast cancer line SUM159 was used to obtain stable SUM159-NTR and SUM159-TK-NTR lines that were tested and found to correspond to the prodrug activity and efficiency pattern obtained through 293T cells. Mice implanted with control cells (SUM159: left shoulder), stable SUM159-NTR cells (lower left flank) and stable SUM159-TK-NTR (lower right flank) were allowed to grow tumors (1-2 mm) for about 2 weeks. Before implantation, the cells (SUM159, SUM159-NTR and SUM159-TK-NTR) were treated with imaging substrate CytoCy5S for 4 h for the intracellular conversion and trapping of fluorescent CytoCy5S inside the cells. The animals were imaged for fluorescence 24 h after initial implantation and 2 weeks later after treatment with both the prodrugs (GCV and CB1954) ( ) from day 1 through day 15, after drug treatment and results are shown in Figure 5a . There was significant therapeutic effect on both the tumors (SUM159-NTR: Po0.05; and SUM159-TK-NTR: Po0.02) compared with corresponding control tumors after two doses of prodrugs (GCV and CB1954) treatment.
In addition, Figure 5b shows a representative animal from a treatment group to further confirm the sizes of different tumors (SUM159, SUM159-NTR and SUM159-TK-NTR), and their morphology in intact animal, and ex vivo dissected from the animal. The photograph is in uniform scale across different tumors to relate the tumor size. However, HSV1-TK-NTR tumor dissected from this particular animal shown in Figure 5b is slightly larger than the NTR-tumor; it was specifically chosen to show the spongy nature of the tumor with the dead cells. Results confirm that degree of both NTR and TK-NTR tumor regression following the treatment was higher than that of control tumor, but the morphology and the color of the TK-NTR (yellow and spongy) tumor was completely different from the control and NTR-tumors.
Immunohistochemical analyses of resected tumor xenografts Two weeks after implantation, animals bearing tumor xenografts of SUM159-NTR, SUM159-TK-NTR and SUM159 control were treated with two dosages of GCV and CB1954 (CB1954 (20 mg kg
) and ganciclovir (25 mg kg À 1 body weight)] on week apart intrapertitoneally Three weeks following the completion of treatment, resected tumors were fixed in formaldehyde, embedded in paraffin blocks, sectioned and H&E stained for necrosis scoring. Left panels of Figure 5c show increased necrosis of TK-NTR tumor tissue (bottom left) when compared with control or NTR tumors. Right panels Figure 5c show results of TUNEL assay on tumor xenografts of SUM159 cells expressing NTR and TK-NTR after the treatment with GCV and CB1954. Tumor tissues fixed in optimal cutting temperature (OCT) were sectioned and processed by an in situ apoptosis detection kit and analyzed for diaminobenzidine staining of apoptotic tissues and cells. In this assay, SUM159-TK-NTR tumor tissues (bottom right) show higher levels of apoptotic cells than control or SUM159-NTR cells, indicating enhanced efficiency of cell death by TK-NTR compared with NTR alone.
DISCUSSION
Despite advances in radiation, chemotherapy and targeted antibody therapies, many patients diagnosed with solid tumors ultimately develop chemoresistance, recurrence or incurable metastatic forms of the diseases. In addition, unequal vascularization and necrosis around tumors hinder the direct access of systemically administered chemotherapeutic drugs to many solid tumors. Therefore, there is an immediate need for development of new tumor-targeted therapeutic strategies that augment conventional treatments by enhancing therapeutic efficiencies for tumors of all stages, including advanced, recurrent and drug-resistant Dual-therapeutic reporter genes fusion TV Sekar et al forms. GDEPT, a suicide gene therapy approach, is uniquely positioned to improve therapeutic index of conventional treatments because its major tenet involves genetic modification of cancer cells that are able to produce tumor-restricted cytotoxic agents from prodrugs, in addition to the ability to kill neighboring tumor cells without affecting normal tissues. As the cytotoxic drug will be produced only in the targeted tumor cells, and will bypass normal cells that do not express the exogenous gene product, higher concentrations of the active drug can be delivered to the tumor, thereby improving the therapeutic index, as compared with conventional systemic chemotherapy. Although both HSV1-TK and NTR systems are effective GDEPT strategies as single-gene systems, earlier clinical studies indicated inadequate beneficial results. Amplifying the degree of therapeutic efficiency by combining multiple genes is known to increase the therapeutic efficiency, 26, 27 and this in fact prompted us to generate a dualsuicide gene system (HSV1-TK-NTR) in order to compare therapeutic efficiencies with single-gene systems. Coupling optical imaging to the multi-gene strategy further allows us to obtain an early indication of efficiency of gene transfer combined with gene function, and to be able to correlate the functionality of the gene with prodrug therapeutic efficacy. In suicide gene therapy, the ability to monitor exogenous gene expression within the targeted tumor of live animals provides validity to the therapeutic effects observed. To monitor therapeutic efficiency in animal models and preclinical studies, the development of safe, sensitive and reproducible non-invasive imaging methods that allow repetitive assessment of bio-distribution, therapeutic efficacy and diagnostic outcome of the agent(s) is of prime importance. 7 In these studies, we used the non-invasive imaging agent CytoCy5S (a novel Cy5-labeled quenched substrate of NTR enzyme), which becomes fluorescent when reduced by the NTR enzyme, remains trapped within the cells for extended periods, and is detectable at 'red-shifted' wavelengths. Using CytoCy5S probe for fluorescent imaging, we have previously assessed the efficacy of CB1954 prodrug on NTR-expressing cells in vitro and on live animal tumor xenografts, 4 and have identified it as a safe and stable agent for NTR-based imaging strategies. Furthermore, the reduced CytoCy5S is stable only in live cell, which has intact cell membrane, hence the release of CytoCy5S can be indirectly used to assess cell death by monitoring the reduced fluorescent signal after treatment (Figure 4) . A limitation of cancer gene therapy is the inability of the gene delivery vector to target every cell within a solid tumor. Presence of a few residual cancer cells results in recurrence of the tumor, especially in solid tumors containing a heterogeneous population of cancer cells. Bystander effect is a valuable outcome of the GDEPT strategy, and is crucial to its success as a tumor-targeted therapy, as the neighboring non-expressing cells are also targeted for cell death. As seen with most GDEPT strategies, including HSV1-TK-GCV, 28 NTR-CB1954 exhibits significant 'bystander killing,' where neighboring tumor cells that escape gene transfer by NTR are killed following cell-cell diffusion of the activated cytotoxic metabolites and apoptotic signaling agents from the transfected cells, allowing for enhancement of antitumor effect even when few tumor cells express the NTR enzyme. 6, 13, 14, 29 Our bystander studies, performed in vitro in 293T cells, were designed to analyze the preliminary bystander effects of the new dual-gene system, HSV1-TK-NTR, and compare it to the NTR and the HSV1-TK strategies. The dual-fusion gene system (HSV1-TK-NTR) found significantly enhanced apoptosis and necrosis on the co-injected control cells, compared to HSV1-TK-or NTR-system, in the presence of the prodrugs GCV and CB1954. HSV1-TK-NTR indicates additive bystander effect due to the presence of two genes, each capable of imparting bystander effect of their own. These preliminary results will allow us to understand and study the bystander effect of the dual-gene system in vivo in the future. Although bystander effect normally kills the neighboring cells the effect to the normal cells is significantly lower when compared to cancer cells. 30 In animal models of tumor xenografts, CB1954 treatment demonstrated regression of tumors stably expressing NTR enzyme, and introduction and expression of NTR in already established tumor xenografts also resulted in potent anti-tumor effects following systemic treatment with CB1954. 29 In our studies, antitumoral effects were dependent solely on prodrug activation by NTR-or HSV1-TK-NTR, as control tumors from non-expressing SUM159 cells were unaffected by prodrug treatments. Monitoring tumors non-invasively by fluorescent CytoCy5 allowed us to determine NTR gene expression and function within cells and tumors, and correlate with tumor regression, while the function of TK was confirmed by in vitro 3 H-PCV uptake assay. Although we did not perform any in vivo imaging to monitor TK expression in animals by this study, it is possible to monitor the expression level of functional TK enzyme in HSV1-TK-NTR fusion for its therapeutic efficiency by 18 F-FHBG mPET imaging. Histological examination of HSV1-TK-NTR-expressing tumor tissue induced by CB1954 and GCV showed the largest amount of apoptotic and necrotic cells, characterized by dense condensed nuclei and significant necrosis at the center of the tumors, indicating that the HSV1-TK-NTR strategy is superior to the NTR-strategy and is capable of targeted regression of breast cancer tumors in mice. Overall, our results indicate that the dual-gene construct HSV1-TK-NTR is functional in targeted tumor cells that both genes HSV1-TK and NTR are effective in activating their respective prodrugs GCV and CB1954, and that the dual-construct imparts enhanced tumor cell killing and bystander effects compared with either of the single-gene constructs alone.
As multi-gene combination systems continue to show promising enhancement of therapeutic efficacies, these strategies can be used in multiple ways to develop future clinical cancer therapies, such as use of a stand-alone multi-gene system (this work) for treatment, or as a supplement to radiation therapy or chemotherapy.
MATERIALS AND METHODS
Generation of expression vectors
The bacterial nitroreductase gene (NTR2), HSV1-thymidine kinase (TK), NTR-HSV1-TK-fusion, and HSV1-TK-NTR-fusion constructs were prepared by cloning PCR-amplified gene fragments in a modified pcDNA 3.1 ( þ ) (Invitrogen, Carlsbad, CA, USA) mammalian expression vectors. The plasmid extraction, DNA gel extraction and genomic DNA extraction kits were purchased from Qiagen (Valencia, CA, USA). NTR gene (nfsB: 642 bp) was PCR-amplified (Triple-Master Mix Taq-DNA polymerase, Brinkmann Eppendorf, Hamburg, Germany) from E.coli (K12) genomic DNA using a forward primer designed with NheI restriction enzyme site (5 0 -ctcgctagcatggatatcatttctgtcgcct-3 0 ) and a reverse primer with XhoI restriction enzyme site (5 0 -tatctcgagttacacttcggttaaggtgat-3 0 ) and cloned into a corresponding enzyme-digested mammalian expression vector pcDNA3.1( þ ) containing a constitutive CMV promoter and puromycin selection marker (Invitrogen) (Supplementary Figure S4) . HSV1-TK gene was PCR amplified with primer set containing NheI (5 0 -ctagctagcatggcttcg tacccctgcca-3 0 ) and XhoI (5 0 -ccgctcgagtcagttagcctcccccatct-3 0 ) sites using the TK-expressing plasmid from our plasmid bank. The NTR, HSV1-TK, NTR-HSV1-TK and HSV1-TK-NTR genes were also cloned with Firefly luciferase (Fluc) reporter under the control of ubiquitin promoter at BglII restriction enzyme site in the same plasmid backbone. All genes and their promoters were sequence confirmed before use.
Cell culture
Cell culture media, fetal bovine serum, antibiotics (streptomycin and penicillin) and lipofectamine 2000 transfection reagent were purchased from Invitrogen. Cell culture plates were purchased from BD Diagnostic Systems (Sparks, MD, USA). 293T cell line (transformed human embryonic kidney, ATCC number CRL-11268) was purchased from American Type Culture Collection (Manassas, VA, USA). SUM159 (triple-negative human breast cancer line) was a kind gift from Dr R Zinn (University of Alabama, Birmingham, AL, USA), and the cells were tested for pathogens by VSC diagnostic lab, Stanford University on May 2011. Overall, 293T cell lines were cultured in Dulbecco's Modified Eagle's Medium (Invitrogen). SUM159 cell line was cultured in F12-Ham's (Invitrogen) medium, 5 mg ml À 1 of insulin and 1 mg ml À 1 of hydrocortisone. All media were supplemented with 10% FBS and 1% penicillin-streptomycin.
Stable lines
Stable lines of SUM159 and 293T cells expressing NTR, HSV1-TK and HSV1-TK-NTR were established by transfecting them with the respective plasmid constructs. Cells (3 Â 10 6 ) were plated in 100-mm culture dishes and allowed to grow to 80% confluency. Thereafter, cells were transfected with respective plasmid construct (5 mg) using lipofectamine 2000 (Invitrogen) transfection reagent, following the manufacturer's recommendations. Transfected cells were treated with puromycin (100 ng ml À 1 ) 24 h post transfection and maintained for several days in the presence of puromycin for selective pressure until B99% cell death. Single colonies of stable cells were expanded and evaluated for the functionality of NTR enzyme by incubating with CytoCy5SS (red-shifted NTR substrate; GE Healthcare, Piscataway, NJ, USA) for the detection of emitted fluorescent signal. CytoCy5SS (excitation 628 nm/emission 638 nm) was dissolved in DMSO to a stock concentration of 2 mg ml À 1 . The substrate was used for all in vitro and in vivo experiments by diluting either in PBS or in cell culture medium. Cells containing luciferase constructs were tested for bioluminescent signals generated by incubation with luciferin substrate and imaging with IVIS imaging system. Clones expressing equivalent levels of NTR and HSV1-TK (as measured by immunoblot analysis) were selected.
Immunoblot analysis
To determine the expression levels of TK in cells transfected with TK and TK-NTR, immunoblot analysis using anti-TK-antibody was performed. Cells were lysed in 100-ml lysis buffer, and 30 mg of total protein from stable cells expressing SUM159-TK and SUM159-TK-NTR, in 1 Â Lamelli loading buffer with b-mercaptoethanol (Bio-Rad) was heated at 95 1C for 5 min, resolved using a 4-12% SDS-polyacrylamide gel electrophoresis gradient gel (Invitrogen), and electroblotted onto a 0.2 mm pore size nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA). The membrane was blocked with 5% non-fat dry milk in tris-buffered saline containing 0.01% Tween-20 (TBS-T, pH 7.6) for 1h and probed overnight at 41C on a rotating platform with the anti-rabbit TK polyclonal antibody. Secondary antibodies were peroxidaseconjugated goat anti-rabbit IgG (1:10 000 dilution, Rockland Immunochemicals, Gilbersville, PA, USA). The membranes were then re-probed with a mouse monoclonal antibody against human a-tubulin (1:5000, clone B-5-1-2, Sigma, St Louis, MO, USA) to control for protein loading. Immunoblots were developed using the LumiGlo enhanced chemiluminescence method (Cell Dual-therapeutic reporter genes fusion TV Sekar et al
Signaling, Boston, MA, USA), following the manufacturer's instructions using blue films (Midwest Scientific, St Louis, MO, USA). -Penciclovir (specific activity 14.9 ci mmol À 1 ; Moravek Biochemicals, La Brea, CA, USA). After 3 h, the cells were washed twice with ice-cold PBS, and lysed in 0.5 ml of 0.1% NaOH, analyzed by scintillation counter by adding scintillation solution. The radioactivity readings were normalized to protein concentrations measured from a 20-ml aliquot of cell lysates. Cells that were not transfected with TK or NTR-TK or TK-NTR were served as control.
Fluorescence-activated cell sorting (FACS)
Ganciclovir (GCV) and 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) were purchased from Sigma-Aldrich (St Louis, MO, USA). Stable cells expressing HSV1-TK, NTR and HSV1-TK-NTR were treated with 1 mg of GCV, and 5 and 10 mM of CB1954. Stable and control cells were seeded in 12-well culture plates and grown to 30-40% confluency followed by 24-h treatment with 1 mg GCV, 5 mM CB1954, 10 mM CB1954, 1 mg GCV þ 5 mM CB1954, 1 mg of GCV þ 10 mM CB1954; untreated cells were used as control. Cells were trypsinized, washed and analyzed for dead or apoptotic cells by staining with propidium iodide (15 nM) or ethidium homodimer-1 (Life Technologies, Grand Island, NY, USA) for 10 min to 2 h, and for viable cells by treatment with calcein AM, followed by flow cytometry (Aria III, BD Biosciences, San Jose, CA, USA) at the Stanford FACS Facility for up to 6 days at 24-h intervals. Data were analyzed by FlowJo FACS analysis software (Tree Star, Ashland, OR, USA).
Bystander effect 293T cells stably co-expressing NTR and EGFP, TK-NTR and EGFP, TK and EGFP, and non-transfected control 293T cells were used to assess bystander effects rendered by the therapeutic reporter gene constructs in vitro. Cells were plated in six-well culture plates with either control 293T or stable 293T cells expressing therapeutic reporter genes in different ratios as shown in Table 1 . The cells were allowed to attach and grow for 24 h before treatment with prodrugs GCV and CB1954. One set was treated with a combination of GCV and CB1954 (1 mg and 10 mM, respectively), whereas the control cells were exposed to respective amounts of solvent DMSO. Both control and treated cells were photographed once every 24 h under a light microscope to monitor the growth and confluence. Following 72 h of treatment, the cells were harvested without trypsin digestion, stained with 15 nM propidium iodide for 10 min, and analyzed in BD FACS ARIA III (BD Biosciences for EGFP and propidium iodide fluorophores. After FACS analysis, the cells in suspension were imaged under a fluorescent microscope for both EGFP and propidium iodide signals.
Tumor xenograft studies and imaging
The Institute Animal Research Committee at Stanford approved all animal handling. All animals (CD1, nude) were purchased from Charles River Laboratories (Wilmington, MA). The mice (N ¼ 7 per treatment) were subcutaneously implanted with 5 Â 10 6 SUM159 triple-negative breast cancer cells stably expressing NTR, stably expressing HSV1-TK, stably coexpressing NTR and TK-genes, and control (wt SUM159) cells on either side of shoulder and lower flanks collected after exposure to 100 ng ml À 1 imaging substrate CytoCy5S for four hours. The tumors were optically imaged for CytoCy5S fluorescent signal, 24 h after implantation. The tumors were allowed to grow for two weeks (1.0 to 2.0 mm in size). The treatment groups were injected with two dosages of prodrug combinations: (1) CB1954 (20 mg kg À 1 ) and ganciclovir (25 mg kg À 1 body weight), and (2) CB1954 (40 mg kg À 1 ) and ganciclovir (50 mg kg À 1 body weight). CytoCy5SS (2.5 mg ml À 1 ), the imaging substrate of NTR, was injected prior to imaging. All animals were imaged before substrate injection to obtain a baseline image by optical CCD camera (IVIS-200 and IVIS-Spectrum Imaging System, Caliper Life Sciences, MA). The animals were imaged by optical imaging camera every 24 h following treatment initiation. The imaging signal and tumor size (Volume-XYZ) from both groups were measured every day and the imaging and treatment continued until the tumor size from the control group reached 1.5 cm in diameter.
TUNEL assay
The tumor xenografts of SUM159 cells expressing various combinations of therapeutic reporter genes after co-treatment with GCV and CB1954 were used for assessing the prodrug-induced therapeutic effects by measuring apoptotic cells. For this, a portion of the tumor was frozen in OCT (TissueTek) and sectioned to 10 mm in a Cryomicrotome (Leica CM1850, Wetzlar, Germany). Terminal deoxynucleotidyltransferase (TdT) nick-end labeling (TUNEL) assay was performed with a Trevigen TACS 2 TdT-DAB (diaminobenzidine) in situ Apoptosis Detection Kit (TREVIGEN, Gaithersburg, MD, USA) according to the manufacturer's instructions. After staining, the slides were scanned in a Nanozoomer 2.0RS (Hamamatsu, Japan) digital scanner, and assessed for diaminobenzidine staining of apoptotic tissues and cells using Nanozoomer digital pathology software.
Histology
Tumor xenografts were frozen in OCT cryoprotective fixing medium, sliced at 5-mm thickness in Leica cryomicrotome and observed under a fluorescent microscope to monitor NTR unquenched CytoCy5S signal trapped in the tissue. Formalin-fixed paraffin-embedded tumor xenografts were processed for histological analysis by H&E staining for necrosis scoring in tumors.
